Concept↦Quality and Risk↦Study Feasibility↦Aim
What is it? Why is it important?
The aim of study feasibility is to evaluate, based on a set of criteria, the likelihood that a study can be conducted, such as:
- Is target population defined and available?
- Does the study provide valuable information (e.g. to target group participants, the therapeutic area)?
- Are selected sites able to conduct the study (e.g. resources, expertise, infrastructure)?
- Based on study type (e.g. ClinO, ClinO-MD, HRO) and risk category (A, B or C), what are the organisational implications (e.g. safety documentation and assessment, additional EC submission, Swissmedic submission, FOPH submission?
- What is the expected budget and financial means?
More
Assessment of study feasibility is based on information gathered at:
SP-INV level
- Potential scientific significance
- Applicable expertise and staff (e.g. project-, data-manager, monitors, statistician)
- Availability of partners (e.g. study site(s), service providers)
- Management of study risks
- Feasibility of study procedures (e.g. randomisation, design)
- Available funds
Site-INV level – as applicable
- Required infrastructure (e.g. storage facilities with access control, work space, computers, patient rooms, laboratory facilities, handling of biological material)
- Resources (e.g. expert physician(s), study nurse or coordinator)
- Availability of target participants (e.g. sufficient number of patients willing to participate)
- Sufficient time available required to conduct the study
What do I need to do?
- Find out how to obtain information on target population at your institution (e.g. number of patients with breast cancer)
- Be up-to-date on scientific questions pertaining to your study (e.g. scientific publications, expert conferences)
- Establish and maintain an important network of experts and colleagues
- Train yourself on setting up a study budget
- Familiarise yourself with risks as defined by the Swiss law
More
When planning a study, many potential risks must be taken into consideration.
In the Swiss law risks are defined based on type of study and its intervention:
- Studies under ClinO
- Medicinal products: Risk category A, B and C with category C having the highest risk
- Other clinical trials: Risk category A and B, with category B having the highest risk
- Studies under ClinO-MD
- Medical Device: Risk category A and C, with category C having the highest risk
- Decisions regarding target population
- Adults, children, adolescents
- Participants with or without capacity
- Participants in an emergency situation
- Type of intervention
- With or without expected direct benefit
- With or without minimal risks and burdens
Depending on risk category the required risk management of the study can vary greatly.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R2) – see in particular guideline
- 5.0 Quality management
ISO 14155 (access liable to costs) – see in particular section
- Medical Device
Swiss Law
HRA – see in particular articles
- Art.16/24 Adults
- 22 Children
- 30/31 Emergency
ClinO – see in particular articles
- Art. 19–22 Risk categorisation of studies with therapeutic and transplant products
- Art. 61 Risk categorisation other clinical studies
ClinO-MD - see in particular article
- Art. 6 Categorisation of clinical investigations